Company

PainReform

As of the edition of 20 October 2026, PainReform runs 2 drugs; it is on route A at 10 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Went quiet2
Total2

Where it needs a new molecule

Route A at 10 targets, route B at 0 targets.

Three of its 10 rows, by target and route
TargetRoute
SCN10A Sodium channel protein type 10 subunit alphaRoute A
SCN5A Sodium channel protein type 5 subunit alphaRoute A
SCN4A Sodium channel protein type 4 subunit alphaRoute A

All 10 rows on route A or B

In the product

10 company-target rows on route A or B; 7 are not shown here, and no score is.